Q2 EPS Forecast for iTeos Therapeutics Decreased by Analyst

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities researchers at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued to clients and investors on Wednesday, May 28th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($0.84) per share for the quarter, down from their prior forecast of ($0.62). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.31) EPS.

ITOS has been the subject of a number of other research reports. Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective (down previously from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Wedbush lowered iTeos Therapeutics from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $10.00 to $12.00 in a report on Wednesday, May 28th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. HC Wainwright downgraded iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $15.86.

iTeos Therapeutics Trading Down 0.5%

Shares of ITOS stock opened at $9.98 on Monday. iTeos Therapeutics has a 12 month low of $4.80 and a 12 month high of $18.13. The company’s fifty day moving average price is $6.99 and its 200-day moving average price is $7.39. The stock has a market cap of $381.97 million, a PE ratio of -3.17 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14.

Insider Buying and Selling

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the transaction, the insider now directly owns 3,452,797 shares of the company’s stock, valued at approximately $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now directly owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. lifted its stake in shares of iTeos Therapeutics by 74.4% in the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company’s stock valued at $21,785,000 after purchasing an additional 1,556,798 shares during the last quarter. BVF Inc. IL lifted its position in shares of iTeos Therapeutics by 32.3% during the first quarter. BVF Inc. IL now owns 3,075,000 shares of the company’s stock worth $18,358,000 after purchasing an additional 750,000 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of iTeos Therapeutics by 342.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after purchasing an additional 1,601,477 shares during the period. 683 Capital Management LLC boosted its position in iTeos Therapeutics by 90.6% in the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company’s stock valued at $10,448,000 after buying an additional 831,883 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in iTeos Therapeutics by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock worth $9,293,000 after purchasing an additional 163,880 shares in the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.